
## Patent Claims

1. Compounds of the formula I



I

in which

X denotes H, $CONH_2$ or CN,

Y denotes NH, N-Me, S or O,

R denotes Ar or Het,

$R^1$ denotes phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothiophenyl, benzofuranyl, imidazopyridyl or furo[3,2-b]pyridyl, each of which is unsubstituted or mono- or disubstituted by Hal, A, $OR^5$, CN, COOA, COOH, $CON(R^5)_2$ and/or $NR^5COA'$,

Ar denotes phenyl, biphenyl or naphtyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, $Het^1$, $(CH_2)_nHet^2$, $(CH_2)_nOR^5$, $(CH_2)_nN(R^5)_2$, $NO_2$, CN, $(CH_2)_nCOOR^5$, $(CH_2)_nCON(R^5)_2$, $CONH(CH_2)_qNHCOOA'$, $CON[R^5(CH_2)_nHet^1]$, $NR^5COA$, NHCOOA, $NR^5SO_2A$, $COR^5$, $SO_2Het^2$, $SO_2N(R^5)_2$ and/or $S(O)_pA$,

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, thiadiazole, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothiophenyl, benzofuranyl or imidazopyridyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, COA, $(CH_2)_pHet^1$, $(CH_2)_pHet^2$, OH, OA, OAr, Hal, $(CH_2)_pN(R^5)_2$, $NO_2$, CN, $(CH_2)_pCOOR^5$, $(CH_2)_pCON(R^5)_2$, $NR^5COA$, $(CH_2)_pCOHet^2$ and/or $(CH_2)_p$phenyl,

$Het^1$ denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl,

thiadiazole, pyridazinyl, pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, OH, OA, Hal, CN and/or $(CH_2)_pCOOR^5$,

$Het^2$ denotes dihydropyrrolyl, pyrrolidinyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl, [1,3]dioxolanyl, piperazinyl, each of which is unsubstituted or monosubstituted by OH, COOA', $CON(R^5)_2$, COA and/or A,

A' denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two non-adjacent CH and/or $CH_2$ groups may be replaced by N, O, S atoms and/or by –CH=CH- groups and/or in addition 1-7 H atoms may be replaced by F,

$R^5$ denotes H or unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2, 3, 4 or 5,

p denotes 0, 1 or 2,

q denotes 1, 2, 3 or 4,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1, in which

$R^1$ denotes phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl or pyrimidyl, each of which is unsubstituted or mono- or disubstituted by A, $OR^5$ and/or CN,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2, in which

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by A, Hal, $(CH_2)_nHet^2$, $(CH_2)_nOR^5$, $(CH_2)_nN(R^5)_2$, $(CH_2)_nCOOR^5$ and/or $(CH_2)_nCON(R^5)_2$,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3, in which

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, thiadiazole, each of which is unsubstituted or mono-, di- or trisubstituted by A, $(CH_2)_pHet^1$, $(CH_2)_pHet^2$, OH, OA, OAr, Hal and/or $(CH_2)_pCOOR^5$,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5. Compounds according to one or more of Claims 1-4, in which

$Het^1$ denotes pyridyl, which is unsubstituted or monosubstituted by A,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

6. Compounds according to one or more of Claims 1-5, in which

$Het^2$ denotes pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or monosubstituted by OH, COOA', $CON(R^5)_2$, COA and/or A,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

7. Compounds according to one or more of Claims 1-6, in which

A denotes unbranched or branched alkyl having 1-8 C atoms, in which one or two non-adjacent CH and/or $CH_2$ groups may be replaced by N and/or O atoms and/or in addition 1-7 H atoms may be replaced by F,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

8. Compounds according to one or more of Claims 1-7, in which

X denotes H, $CONH_2$ or CN,

R denotes Ar or Het,

$R^1$ denotes phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl or pyrimidyl, each of which is unsubstituted or mono- or disubstituted by A, $OR^5$ and/or CN,

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by A, Hal, $(CH_2)_nHet^2$, $(CH_2)_nOR^5$, $(CH_2)_nN(R^5)_2$, $(CH_2)_nCOOR^5$ and/or $(CH_2)_nCON(R^5)_2$,

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, thiadiazole, each of which is unsubstituted or mono-, di- or trisubstituted by A, $(CH_2)_pHet^1$, $(CH_2)_pHet^2$, OH, OA, OAr, Hal and/or $(CH_2)_pCOOR^5$,

$Het^1$ denotes pyridyl, which is unsubstituted or monosubstituted by A,

$Het^2$ denotes pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or monosubstituted by OH, COOA', $CON(R^5)_2$, COA and/or A,

A' denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F,

A denotes unbranched or branched alkyl having 1-8 C atoms, in which one or two non-adjacent CH and/or $CH_2$ groups may be replaced by N and/or O atoms and/or in addition 1-7 H atoms may be replaced by F,

$R^5$ denotes H or unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2, 3, 4 or 5,

p denotes 0, 1 or 2,

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

9. Compounds according to Claim 1, selected from the group

| compound nr. | name |
|---|---|
| "A1" | 5-(3,4-dimethoxy-benzoylamino)-2-phenyl-thiazole-4-carboxylic acid amide |
| "A2" | 5-[(3,4-dimethoxybenzoyl)amino]-2-pyrid-3-yl-1,3-thiazole-4-carboxamide |
| "A3" | 4-[4-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-benzyl]-piperazine-1-carboxylic acid tert.-butyl ester |
| "A4" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A5" | 2-(2-chloro-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A6" | 2-(2-fluoro-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A7" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-2-(2-methyl-pyridin-4-yl)-thiazole-4-carboxylic acid amide |
| "A8" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-2-(2-trifluoromethyl-pyridin-4-yl)-thiazole-4-carboxylic acid amide |
| "A9" | 2-(2-cyano-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A10" | 2-(4-fluoro-phenyl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A11" | 2-(4-methanesulfonyl-phenyl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A12" | 4-{4-carbamoyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazol-2-yl}-benzoic acid methyl ester |
| "A13" | 2-(4-methoxy-phenyl)-5-[4-(4-methyl-piperazin-1-ylmethyl)- |

| | |
|---|---|
| | benzoylamino]-thiazole-4-carboxylic acid amide |
| "A14" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A15" | 4-(4-methyl-piperazin-1-ylmethyl)-N-(2-pyridin-4-yl-thiazol-5-yl)-benzamide |
| "A16" | 2-(2,6-dimethyl-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A17" | 5-[4-(4-Methyl-piperazin-1-ylmethyl)-benzoylamino]-2-(3-trifluoromethyl-pyridin-4-yl)-thiazole-4-carboxylic acid amide |
| "A18" | 2-(3-bromo-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A19" | 2-(3-fluoro-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A20" | 2-(3-chloro-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A21" | 2-(3-methoxy-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A22" | 2-(3-methyl-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A23" | 4-[4-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-benzyl]-piperidine-1-carboxylic acid amide |
| "A24" | 5-(4-piperazin-1-ylmethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A25" | 5-[4-(4-dimethylcarbamoyl-butyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A26" | 5-[4-(1-methyl-piperidin-4-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A27" | 5-[4-(4-acetyl-piperazin-1-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A28" | 6-[4-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-phenyl]-hexanoic acid |
| "A29" | 5-(4-piperidin-4-ylmethyl-benzoylamino)-2-pyridin-4-yl-thiazole- |

| | |
|---|---|
| | 4-carboxylic acid amide |
| "A30" | 5-[4-(1-acetyl-piperidin-4-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A31" | 5-{4-[(2-dimethylamino-ethylamino)-methyl]-benzoylamino}-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A32" | 5-[4-(4-methylcarbamoyl-butyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A33" | 5-{4-[(2-methoxy-ethylamino)-methyl]-benzoylamino}-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A34" | 5-[4-(4-methyl-piperazine-1-carbonyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A35" | 5-[4-(5-dimethylcarbamoyl-pentyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A36" | 5-(4-morpholin-4-ylmethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A37" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A38" | 2-pyridin-4-yl-5-(4-pyrrolidin-1-ylmethyl-benzoylamino)-thiazole-4-carboxylic acid amide |
| "A39" | 4-[5-(4-Carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester |
| "A40" | 5-(4-dimethylaminomethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A41" | 5-(3,4-dimethoxy-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A42" | 5-[(1H-pyrazole-4-carbonyl)-amino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A43" | N-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-yl)-6-morpholin-4-yl-nicotinamide |
| "A44" | 5-[(1-piperidin-4-ylmethyl-1H-pyrazole-4-carbonyl)-amino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A45" | N-(4-cyano-2-pyridin-4-yl-thiazol-5-yl)-4-(4-methyl-piperazin-1- |


| | |
|---|---|
| | ylmethyl)-benzamide |
| "A46" | 5-(4-morpholin-4-ylmethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A47" | 5-(4-pentyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A48" | 5-(4-hexyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A49" | 5-{3-[4-(4-methyl-piperazin-1-yl)-phenyl]-ureido}-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A50" | 5-[4-(4-carbamoyl-butyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A51" | N-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-yl)-2-(4-chloro-phenoxy)-nicotinamide |
| "A52" | N-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-yl)-2-phenoxy-nicotinamide |
| "A53" | 5-{[1-(6-methyl-pyridin-2-yl)-1H-imidazole-4-carbonyl]-amino}-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A54" | 2-(2,6-dimethyl-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A55" | 5-(4-methylbenzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid |
| "A56" | 5-benzoylamino-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A57" | 5-{[4-(dimethylamino)benzoyl]amino}-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A58" | 5-[(4-aminobenzoyl)amino]-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A59" | 5-{[(1-methyl-1*H*-pyrrol-2-yl)carbonyl]amino}-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A60" | 5-(2-furoylamino)-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A61" | 2-pyridin-4-yl-5-[(1*H*-pyrrol-2-ylcarbonyl)amino]-1,3-thiazole-4-carboxamide |
| "A62" | 2-pyridin-4-yl-5-[(2-thienylcarbonyl)amino]-1,3-thiazole-4- |

| | carboxamide |
|---|---|
| "A63" | 5-[(1*H*-pyrazol-3-ylcarbonyl)amino]-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A64" | 5-(3-furoylamino)-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A65" | 2-pyridin-4-yl-5-[(3-thienylcarbonyl)amino]-1,3-thiazole-4-carboxamide |

and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

10. Process for the preparation of compounds of the formula I according to Claims 1-9 and pharmaceutically usable salts, tautomers and stereoisomers thereof, characterised in that

a) a compound of the formula II




II ,

in which X, Y and $R^1$ have the meanings indicated in Claim 1,

is reacted with a compound of formula III

R-CO-L III

in which R has the meaning indicated in Claim1 and
L denotes Cl, Br, I or a free or reactively functionally modified OH group,

or

b) that it is liberated from one of its functional derivatives by treatment with a solvolysing or hydrogenolysing agent,

and/or
a base or acid of the formula I is converted into one of its salts.

11. Medicaments comprising at least one compound of the formula I according to Claim 1-9 and/or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.


12. Compounds according to Claim 1-9 and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment of cancer, septic shock, Primary open Angle Glaucoma (POAG), hyperplasia, rheumatoid arthritis, psoriasis, artherosclerosis, retinopathy, osteoarthritis, endometriosis, chronic inflammation, and/or neurodegenerative diseases.

13. Compounds of the formula I according to Claim 1-9 and/or physiologically acceptable salts, tautomers and stereoisomers thereof for the use for the treatment of tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.

14. Compounds of the formula I according to Claim 1-9 and/or physiologically acceptable salts, tautomers and stereoisomers thereof for the use for the treatment of tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6)

prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.

1. A compound of formula I




I

wherein:

X denotes $CONH_2$,

Y denotes S,

R denotes Ar or Het,

$R^1$ denotes phenyl

Ar denotes phenyl, biphenyl or naphtyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, $Het^1$, $(CH_2)_nHet^2$, $(CH_2)_nOR^5$, $(CH_2)_nN(R^5)_2$, $NO_2$, CN, $(CH_2)_nCOOR^5$, $(CH_2)_nCON(R^5)_2$, $CONH(CH_2)_qNHCOOA'$, $CON[R^5(CH_2)_nHet^1]$, $NR^5COA$, NHCOOA, $NR^5SO_2A$, $COR^5$, $SO_2Het^2$, $SO_2N(R^5)_2$ or $S(O)_pA$,

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, thiadiazole, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothiophenyl, benzofuranyl or imidazopyridyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, COA, $(CH_2)_pHet^1$, $(CH_2)_pHet^2$, OH, OA, OAr, Hal, $(CH_2)_pN(R^5)_2$, $NO_2$, CN, $(CH_2)_pCOOR^5$, $(CH_2)_pCON(R^5)_2$, $NR^5COA$, $(CH_2)_pCOHet^2$ or $(CH_2)_p$phenyl,

$Het^1$ denotes pyridyl, which is unsubstitued or monosubstituted by A,

$Het^2$ denotes pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstitued or monosubstituted by OH, COOA', $CON(R^5)_2$, COA or A,

A' denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two non-adjacent CH and/or $CH_2$ groups may be replaced by N, O, S atoms and/or by –CH=CH- groups and/or in addition 1-7 H atoms may be replaced by F,

$R^5$ denotes H or unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2, 3, 4 or 5,

p denotes 0, 1 or 2,

q denotes 1, 2, 3 or 4,

and pharmaceutically usable salts, tautomers and stereoisomers thereof

2. The compound of claim 1, wherein:

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by A, Hal, $(CH_2)_nHet^2$, $(CH_2)_nOR^5$, $(CH_2)_nN(R^5)_2$, $(CH_2)_nCOOR^5$ or $(CH_2)_nCON(R^5)_2$,

and pharmaceutically usable salts, tautomers and stereoisomers thereof

3. The compound of claim 1, wherein:

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, thiadiazole, each of which is unsubstituted or mono-, di- or trisubstituted by A, $(CH_2)_pHet^1$, $(CH_2)_pHet^2$, OH, OA, OAr, Hal or $(CH_2)_pCOOR^5$,

and pharmaceutically usable salts, tautomers and stereoisomers thereof

4. The compound of claim 2, wherein:

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, thiadiazole, each of which is unsubstituted or mono-, di- or trisubstituted by A, $(CH_2)_pHet^1$, $(CH_2)_pHet^2$, OH, OA, OAr, Hal or $(CH_2)_pCOOR^5$,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

5. The compound of claim 1, wherein:

$Het^1$ denotes pyridyl, which is unsubstituted or monosubstituted by A,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

6. The compound of claim 2, in which:

$Het^1$ denotes pyridyl, which is unsubstituted or monosubstituted by A,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

7. The compound of claim 1, in which:

$Het^2$ denotes pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or monosubstituted by OH, COOA', $CON(R^5)_2$, COA or A,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

8. The compound of claim 2, in which:

$Het^2$ denotes pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or monosubstituted by OH, COOA', $CON(R^5)_2$, COA or A,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

9. The compound of claim 3, in which:

$Het^2$ denotes pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or monosubstituted by OH, COOA', $CON(R^5)_2$, COA or A,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

10. The compound of claim 1, in which:

A denotes unbranched or branched alkyl having 1-8 C atoms, in which one or two non-adjacent CH and/or $CH_2$ groups may be replaced by N or O atoms or in addition 1-7 H atoms may be replaced by F,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

11. The compound of claim 2, in which:

A denotes unbranched or branched alkyl having 1-8 C atoms, in which one or two non-adjacent CH and/or $CH_2$ groups may be replaced by N or O atoms or in addition 1-7 H atoms may be replaced by F,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

12. The compound of claim 3, in which:

A denotes unbranched or branched alkyl having 1-8 C atoms, in which one or two non-adjacent CH and/or $CH_2$ groups may be replaced by N or O atoms or in addition 1-7 H atoms may be replaced by F,

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

13. A compound selected from the group consisting of:

| Compound No. | name |
|---|---|
| "A1" | 5-(3,4-dimethoxy-benzoylamino)-2-phenyl-thiazole-4-carboxylic acid amide |
| "A2" | 5-[(3,4-dimethoxybenzoyl)amino]-2-pyrid-3-yl-1,3-thiazole-4-carboxamide |
| "A3" | 4-[4-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-benzyl]-piperazine-1-carboxylic acid tert.-butyl ester |
| "A4" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A5" | 2-(2-chloro-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A6" | 2-(2-fluoro-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A7" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-2-(2-methyl-pyridin-4-yl)-thiazole-4-carboxylic acid amide |
| "A8" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-2-(2-trifluoromethyl-pyridin-4-yl)-thiazole-4-carboxylic acid amide |
| "A9" | 2-(2-cyano-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A10" | 2-(4-fluoro-phenyl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A11" | 2-(4-methanesulfonyl-phenyl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A12" | 4-{4-carbamoyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazol-2-yl}-benzoic acid methyl ester |
| "A13" | 2-(4-methoxy-phenyl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A14" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A15" | 4-(4-methyl-piperazin-1-ylmethyl)-N-(2-pyridin-4-yl-thiazol-5-yl)-benzamide |

| | |
|---|---|
| "A16" | 2-(2,6-dimethyl-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A17" | 5-[4-(4-Methyl-piperazin-1-ylmethyl)-benzoylamino]-2-(3-trifluoromethyl-pyridin-4-yl)-thiazole-4-carboxylic acid amide |
| "A18" | 2-(3-bromo-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A19" | 2-(3-fluoro-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A20" | 2-(3-chloro-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A21" | 2-(3-methoxy-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A22" | 2-(3-methyl-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A23" | 4-[4-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-benzyl]-piperidine-1-carboxylic acid amide |
| "A24" | 5-(4-piperazin-1-ylmethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A25" | 5-[4-(4-dimethylcarbamoyl-butyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A26" | 5-[4-(1-methyl-piperidin-4-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A27" | 5-[4-(4-acetyl-piperazin-1-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A28" | 6-[4-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-phenyl]-hexanoic acid |
| "A29" | 5-(4-piperidin-4-ylmethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A30" | 5-[4-(1-acetyl-piperidin-4-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A31" | 5-{4-[(2-dimethylamino-ethylamino)-methyl]-benzoylamino}-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |

| | |
|---|---|
| "A32" | 5-[4-(4-methylcarbamoyl-butyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A33" | 5-{4-[(2-methoxy-ethylamino)-methyl]-benzoylamino}-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A34" | 5-[4-(4-methyl-piperazine-1-carbonyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A35" | 5-[4-(5-dimethylcarbamoyl-pentyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A36" | 5-(4-morpholin-4-ylmethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A37" | 5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A38" | 2-pyridin-4-yl-5-(4-pyrrolidin-1-ylmethyl-benzoylamino)-thiazole-4-carboxylic acid amide |
| "A39" | 4-[5-(4-Carbamoyl-2-pyridin-4-yl-thiazol-5-ylcarbamoyl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester |
| "A40" | 5-(4-dimethylaminomethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A41" | 5-(3,4-dimethoxy-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A42" | 5-[(1H-pyrazole-4-carbonyl)-amino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A43" | N-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-yl)-6-morpholin-4-yl-nicotinamide |
| "A44" | 5-[(1-piperidin-4-ylmethyl-1H-pyrazole-4-carbonyl)-amino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A45" | N-(4-cyano-2-pyridin-4-yl-thiazol-5-yl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide |
| "A46" | 5-(4-morpholin-4-ylmethyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A47" | 5-(4-pentyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |

| | |
|---|---|
| "A48" | 5-(4-hexyl-benzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A49" | 5-{3-[4-(4-methyl-piperazin-1-yl)-phenyl]-ureido}-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A50" | 5-[4-(4-carbamoyl-butyl)-benzoylamino]-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A51" | N-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-yl)-2-(4-chloro-phenoxy)-nicotinamide |
| "A52" | N-(4-carbamoyl-2-pyridin-4-yl-thiazol-5-yl)-2-phenoxy-nicotinamide |
| "A53" | 5-{[1-(6-methyl-pyridin-2-yl)-1H-imidazole-4-carbonyl]-amino}-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A54" | 2-(2,6-dimethyl-pyridin-4-yl)-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-thiazole-4-carboxylic acid amide |
| "A55" | 5-(4-methylbenzoylamino)-2-pyridin-4-yl-thiazole-4-carboxylic acid |
| "A56" | 5-benzoylamino-2-pyridin-4-yl-thiazole-4-carboxylic acid amide |
| "A57" | 5-{[4-(dimethylamino)benzoyl]amino}-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A58" | 5-[(4-aminobenzoyl)amino]-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A59" | 5-{[(1-methyl-1*H*-pyrrol-2-yl)carbonyl]amino}-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A60" | 5-(2-furoylamino)-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A61" | 2-pyridin-4-yl-5-[(1*H*-pyrrol-2-ylcarbonyl)amino]-1,3-thiazole-4-carboxamide |
| "A62" | 2-pyridin-4-yl-5-[(2-thienylcarbonyl)amino]-1,3-thiazole-4-carboxamide |
| "A63" | 5-[(1*H*-pyrazol-3-ylcarbonyl)amino]-2-pyridin-4-yl-1,3-thiazole-4-carboxamide |
| "A64" | 5-(3-furoylamino)-2-pyridin-4-yl-1,3-thiazole-4-carboxamide and |
| "A65" | 2-pyridin-4-yl-5-[(3-thienylcarbonyl)amino]-1,3-thiazole-4-carboxamide |

and pharmaceutically usable salts, tautomers and stereoisomers thereof.

14. A medicament comprising: i) a compound of the formula I according to claim 1 and ii) pharmaceutically usable salts, tautomers and stereoisomers thereof.